Efficacy and Safety of AngongNiuhuang Pill for the Treatment of Patients With Acute Ischemic Stroke. (AGNH2018)

AngongNiuhuang pill has obvious effects on the cardiovascular and cerebrovascular, especially the cerebral vessels. Pharmacological experiments confirmed that AngongNiuhuang pill can protect blood-brain barrier, reduce capillary permeability, improve the tolerance of cerebral ischemia and hypoxia, improve oxidative stress injury, thus protecting brain tissue. Clinical studies have also confirmed that AngongNiuhuang pill can increase the GCS score, reduce coma, improve nerve function defect and promote nerve function recovery. The primary purpose of this trial was to evaluate the effect of AngongNiuhuang pill and placebo on the improvement of life function in patients with ischemic stroke at 90 days in acute phase.

Study Overview

• Status: Unknown
• Conditions: Acute Ischemic Stroke
• Intervention / Treatment: Drug: AngongNiuhuang pill; Other: Standard treatment; Drug: Placebo of AngongNiuhuang pill

Detailed Description

This trial is a prospective, randomized, double-blinded, placebo parallel controlled, multiple-center trial. A total of approximately 100 patients (18 years ≤age ≤80 years) within 24 hours of symptom onset of acute ischemic stroke, who shows NIHSS from 5-20 points. Patients fulfilling all of the inclusion criteria and none of the exclusion criteria will be randomized 1:1 into two groups after offering informed content: 1) one group will receive AngongNiuhuang pill 1 pill 1 times/day for 5-day; 2) the other group will receive Placebo of AngongNiuhuang pill 1 pill 1 times/day for 5-day.The primary purpose of this trial was to evaluate the effect of AngongNiuhuang pill and placebo on the improvement of life function in patients with ischemic stroke at 90 days in acute phase. The study consists of five visits including the day of randomization, 2-6 days, monitor daily temperature, 7 days when the therapy is done, 30 days, and 90 days when the follow-up is finished. Demographic information, symptoms and signs, laboratory test, neuro-imaging assessment neurological function rating scale will be recorded during the program. The improvement of life function will be assessed by Modified Rankin Scale(namely score=0-2). The trial is anticipated to last from July 2018 to December 2019 with 100 subjects recruited form 5 centers in China. All the related investigative organization and individuals will obey the Declaration of Helsinki and Chinese GCP standard. A Data and Safety Monitoring Board (DSMB) will regularly monitor safety during the study.

• Study Type: Interventional
• Enrollment (Anticipated): 100
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Shengde Li, MD; Phone Number: 86-17896002828; Email: lishengde.medicine@qq.com
• Study Contact Backup: Name: Bin Peng, MD; Phone Number: 86-10-69156371; Email: pengbin3@hotmail.com

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100730
      • Bin Peng
      • Contact: Shengde Li, MD; Phone Number: 86-17896002828; Email: lishengde.medicine@qq.com
      • Contact: Bin Peng, MD; Phone Number: 86-10-69156371; Email: pengbin3@hotmail.com
      • Sub-Investigator: Zunjing Liu, MD
      • Sub-Investigator: Rusheng Shao, MD
      • Sub-Investigator: Zhenzhong Li, MD
      • Sub-Investigator: Yanjun Gao, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Acute ischemic stroke.
2. 18 years ≤ age ≤ 80 years.
3. Within 24 hours from symptom onset.
4. Baseline NIHSS range 5 from 20.
5. Provision of informed consent.

Exclusion Criteria:

1. Not suitable for taking this medicine after dialectic of traditional Chinese medical doctor.
2. Suffering from intracranial tumors, encephalitis, subarachnoid hemorrhage and other brain organic diseases.
3. Receive thrombolysis or endovascular treatment.
4. mRS>1 at randomization (pre-morbid historical assessment).
5. Thrombocytopenia(<100×10*9/L) , hematologic diseases and other systemic bleeding tendency.
6. Sleepy head (GCS≤7).
7. Alanine transaminase > 1.5 times normal upper limit or Aspartate aminotransferase > 1.5 times normal upper limit.
8. Glomerular filtration rate<60 ml/min/1.73m2.
9. Patients who have been taking AngongNiuhuang pills within 3 months.
10. Pregnancy or lactation, women in childbearing age with negative pregnancy test refuse to accept contraception.
11. Participate in clinical studies of other research drugs within the last 30 days.
12. Patients with a life expectancy of less than three months.
13. Incapable to follow this study for mental illness, cognitive or emotional disorders.
14. Unsuitable for this study in the opinion of the investigators.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: AngongNiuhuang; Drugs: AngongNiuhuang pill. The other treatments will be provided according to guidelines for standard treatment of acute ischemic stroke.	Drug: AngongNiuhuang pill; This group will receive AngongNiuhuang pill 1 pill 1 times/day for 5-day.; Other: Standard treatment; The other treatments according to guidelines for standard treatment of acute ischemic stroke.
Placebo Comparator: Placebo of AngongNiuhuang; Drugs: Placebo of AngongNiuhuang pill. The other treatments will be provided according to guidelines for standard treatment of acute ischemic stroke.	Other: Standard treatment; The other treatments according to guidelines for standard treatment of acute ischemic stroke.; Drug: Placebo of AngongNiuhuang pill; This group will receive Placebo of AngongNiuhuang pill 1 pill 1 times/day for 5-day.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The proportion of patients achieve favorable clinical outcomes assessed by Modified Rankin Scale(namely score=0-2)	Modified Rankin Scale score changes (continuous) and dichotomized at percentage with score 0-2 vs. 3-6 at the 90 days follow-up.	90days
Severity Adverse Event	The percentage of the Severity Adverse Events within the 90 days of the therapy.	90days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The proportion of patients achieve favorable clinical outcomes assessed by Modified Rankin Scale(namely score=0-2)	Modified Rankin Scale score changes (continuous) and dichotomized at percentage.	7days, 30days
Neurological recovery	The recovery of neurological deficits assessed by the change of the 7days, 30 days and the 90 days NIHSS to the baseline NIHSS.	7 days, 30 days,90 days
Barthel Index	Change in the score of the Barthel Index.（The Barthel Index (BI) measures 10 basic aspects of self-care and physical dependency, including 10 subscales: feeding, bathing, grooming, dressing, bowels, bladder, toilet use, transfers, mobility, and stairs. Every subscale ranges from 0 to 10. Its total score range is 0-100. A normal score is 100, and lower scores indicate increasing disability.）	30 days, 90 days
Recurrent stroke, death and other vascular events	The quantity of patients who has recurrent stroke, death and other vascular events.	30 days, 90 days
Changes of biomarker (hs-CRP)	Evaluation of the change in (centralization blood sample determination).	7 days
Changes of biomarker (IL-10)	Evaluation of the change in IL-10 (centralization blood sample determination).	7days
Changes of biomarker (TNF-α)	Evaluation of the change in TNF-α level (centralization blood sample determination).	7days
Adverse Events	The percentage of the Adverse Events during the therapy.	7 days, 90 days
Severity Adverse Event	The percentage of the Severity Adverse Events during the therapy.	7days

Collaborators and Investigators

• Sponsor: Peking Union Medical College Hospital
• Collaborators: The Second Hospital of Hebei Medical University; China-Japan Friendship Hospital; Cangzhou Central Hospital; Affiliated Hospital of Chengde Medical University
• Investigators: Principal Investigator: Bin Peng, MD, Peking Union Medical College

Study record dates

Study Major Dates

• Study Start (Anticipated): December 1, 2018
• Primary Completion (Anticipated): December 30, 2019
• Study Completion (Anticipated): December 30, 2019

Study Registration Dates

• First Submitted: November 1, 2018
• First Submitted That Met QC Criteria: November 6, 2018
• First Posted (Actual): November 7, 2018

Study Record Updates

• Last Update Posted (Actual): November 7, 2018
• Last Update Submitted That Met QC Criteria: November 6, 2018
• Last Verified: November 1, 2018

More Information

Terms related to this study

• Keywords: acute ischemic stroke; AngongNiuhuang pill
• Additional Relevant MeSH Terms: Pathologic Processes; Necrosis; Cardiovascular Diseases; Vascular Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Brain Ischemia; Infarction; Brain Infarction; Stroke; Ischemic Stroke; Ischemia; Cerebral Infarction
• Other Study ID Numbers: PUMCH-AGNH2018

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No